<!DOCTYPE html>

<html lang="en" data-theme="light">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Pharmacokinetics: Membrane Transport - Essentials of Medical Pharmacology</title>

<link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">

<link rel="stylesheet" href="../styles/main.css">

<script>
MathJax = {
    tex: {
        inlineMath: [['$', '$'], ['\\(', '\\)']],
        displayMath: [['$$', '$$'], ['\\[', '\\]']],
        processEscapes: true,
        processEnvironments: true
    },
    svg: { fontCache: 'global' },
    options: {
        skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
    }
};
</script>
<script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
<a href="#main-content" class="skip-link">Skip to main content</a>

code
Code
download
content_copy
expand_less
<button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
    <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
    <span class="theme-toggle-icon dark-icon">üåô</span>
</button>

<div class="reading-progress-container">
    <div class="reading-progress-bar" id="reading-progress"></div>
</div>

<!-- Floating TOC -->
<nav class="floating-toc" id="floating-toc">
    <div class="floating-toc-header">
        <span>üìë</span> Table of Contents
    </div>
    <ul class="floating-toc-list">
        <li><a href="#membrane-transport">Membrane Transport</a></li>
        <li><a href="#absorption">Absorption</a></li>
        <li><a href="#bioavailability">Bioavailability</a></li>
        <li><a href="#distribution">Distribution</a></li>
        <li><a href="#protein-binding">Plasma Protein Binding</a></li>
        <li><a href="#problem-study">Problem Directed Study</a></li>
    </ul>
</nav>

<div class="page-wrapper">
    <div class="container">
        <article class="document-article">
            <header class="document-header">
                <div class="header-badge">
                    <span>üíä</span>
                    <span>Topic 02</span>
                </div>
                <h1 class="document-title">Pharmacokinetics: Membrane Transport, Absorption and Distribution of Drugs</h1>
                <div class="title-meta">
                    <div class="meta-item">
                        <span>üìö</span>
                        <span>General Pharmacological Principles</span>
                    </div>
                    <div class="meta-item">
                        <span>‚è±Ô∏è</span>
                        <span>35 min read</span>
                    </div>
                </div>
            </header>

            <main id="main-content" class="content-wrapper">
                <!-- Section 1: Introduction -->
                <section class="content-section" id="membrane-transport">
                    <div class="section-header">
                        <div class="section-number">01</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß¨</span>
                            Membrane Transport
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Pharmacokinetics is the quantitative study of drug movement in, through and out of the body. The overall scheme of pharmacokinetic processes is depicted in Fig. 2.1. The intensity of response is related to concentration of the drug at the site of action, which in turn is dependent on its pharmacokinetic properties. Pharmacokinetic considerations, therefore, determine the route(s) of administration, dose, latency of onset, time of peak action, duration of action and frequency of administration of a drug.</p>
                        
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-a2359ab8.jpeg" alt="Schematic depiction of pharmacokinetic processes" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.1: Schematic depiction of pharmacokinetic processes</figcaption>
                        </figure>

                        <p>All pharmacokinetic processes involve transport of the drug across biological membranes.</p>
                        
                        <div class="callout callout--info">
                            <div class="callout-header">
                                <span class="callout-icon">üî¨</span>
                                <h4 class="callout-title">Biological Membrane</h4>
                            </div>
                            <div class="callout-content">
                                <p>This is a bilayer (about 100 √Ö thick) of phospholipid and cholesterol molecules, the polar groups (glyceryl phosphate attached to ethanolamine/choline or hydroxyl group of cholesterol) of these are oriented at the two surfaces and the nonpolar hydrocarbon chains are embedded in the matrix to form a continuous sheet. This imparts high electrical resistance and relative impermeability to the membrane.</p>
                            </div>
                        </div>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-438fae79.jpeg" alt="Illustration of the organisation of biological membrane" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.2: Illustration of the organisation of biological membrane</figcaption>
                        </figure>

                        <p>Extrinsic and intrinsic protein molecules are adsorbed on the lipid bilayer (Fig. 2.2). Glycoproteins or glycolipids are formed on the surface by attachment to polymeric sugars, aminosugars or sialic acids. The specific lipid and protein composition of different membranes differs according to the cell or the organelle type. The proteins are able to freely float through the membrane: associate and organize or vice versa. Some of the intrinsic ones, which extend through the full thickness of the membrane, surround fine aqueous pores. Paracellular spaces or channels also exist between certain epithelial/endothelial cells. Other adsorbed proteins have enzymatic, carrier, receptor or signal transduction properties. Lipid molecules also are capable of lateral movement. Thus, biological membranes are highly dynamic structures.</p>
                        <p>Drugs are transported across the membranes by:<br>
                        (a) Passive diffusion and filtration<br>
                        (b) Specialized transport</p>

                        <h3>Passive diffusion</h3>
                        <p>The drug diffuses across the membrane in the direction of its concentration gradient (high to low), the membrane playing no active role in the process. This is the most important mechanism for majority of drugs; drugs are foreign substances (xenobiotics), and specialized mechanisms are developed by the body primarily for normal metabolites.</p>
                        
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-1ceb2ee3.jpeg" alt="Illustration of passive diffusion and filtration across the lipoidal biological membrane with aqueous pores" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.3: Illustration of passive diffusion and filtration across the lipoidal biological membrane with aqueous pores</figcaption>
                        </figure>

                        <p>Lipid soluble drugs diffuse by dissolving in the lipoidal matrix of the membrane (Fig. 2.3), the rate of transport being proportional to the lipid : water partition coefficient of the drug. A more lipid-soluble drug attains higher concentration in the membrane and diffuses quickly. Also, greater the difference in the concentration of the drug on the two sides of the membrane, faster is its diffusion.</p>
                        
                        <h4>Influence of pH</h4>
                        <p>Most drugs are weak electrolytes, i.e. their ionization is pH dependent (contrast strong electrolytes that are nearly completely ionized at acidic as well as alkaline pH). The ionization of a weak acid HA is given by the equation:</p>
                        
                        <div class="equation">
                            $$p H=p K a+\log \frac{\left[\mathrm{A}^{-}\right]}{[\mathrm{HA}]}$$
                        </div>

                        <p>$pKa$ is the negative logarithm of acidic dissociation constant of the weak electrolyte. If the concentration of ionized drug $[\mathrm{A}^{-}]$ is equal to concentration of unionized drug $[\mathrm{HA}]$, then</p>
                        
                        <div class="equation">
                            $$\frac{\left[\mathrm{A}^{-}\right]}{[\mathrm{HA}]}=1$$
                        </div>

                        <p>since $\log 1$ is 0, under this condition</p>
                        
                        <div class="equation">
                            $$p H=p K a$$
                        </div>

                        <p>Thus, $pKa$ is numerically equal to the pH at which the drug is 50% ionized.</p>
                        <p>If pH is increased by 1 scale, then‚Äî</p>
                        <div class="equation">
                            $$\log \left[\mathrm{A}^{-}\right] /[\mathrm{HA}]=1 \quad \text { or } \quad\left[\mathrm{A}^{-}\right] /[\mathrm{HA}]=10$$
                        </div>
                        <p>Similarly, if pH is reduced by 1 scale, then‚Äî</p>
                        <div class="equation">
                            $$\left[\mathrm{A}^{-}\right] /[\mathrm{HA}]=1 / 10$$
                        </div>

                        <p>Thus, weakly acidic drugs, which form salts with cations, e.g. sod. phenobarbitone, sod. sulfadiazine, pot. penicillin-V, etc. ionize more at alkaline pH and 1 scale change in pH causes 10 fold change in ionization.</p>
                        <p>Weakly basic drugs, which form salts with anions, e.g. atropine sulfate, ephedrine HCl, chloroquine phosphate, etc. conversely ionize more at acidic pH. Ions being lipid insoluble, do not diffuse and a pH difference across a membrane can cause differential distribution of weakly acidic and weakly basic drugs on the two sides (Fig. 2.4).</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-c25b0b2f.jpeg" alt="Influence of pH difference on two sides of a biological membrane" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.4: Influence of pH difference on two sides of a biological membrane on the steady-state distribution of a weakly acidic drug with pKa = 6</figcaption>
                        </figure>

                        <p>Implications of this consideration are:</p>
                        <ul class="enhanced-list">
                            <li class="list-item">
                                <span class="list-marker">a</span>
                                <span class="list-content">Acidic drugs, e.g. aspirin ($pKa$ 3.5) are largely unionized at acid gastric pH and are absorbed from stomach, while bases, e.g. atropine ($pKa$ 10) are largely ionized and are absorbed only when they reach the intestines.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">b</span>
                                <span class="list-content">The unionized form of acidic drugs which crosses the surface membrane of gastric mucosal cell, reverts to the ionized form within the cell (pH 7.0) and then only slowly passes to the extracellular fluid. This is called <strong>ion trapping</strong>, i.e. a weak electrolyte crossing a membrane to encounter a pH from which it is not able to escape easily. This may contribute to gastric mucosal cell damage caused by aspirin.</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">c</span>
                                <span class="list-content">Basic drugs attain higher concentration intracellularly (pH 7.0 vs 7.4 of plasma).</span>
                            </li>
                            <li class="list-item">
                                <span class="list-marker">d</span>
                                <span class="list-content">Acidic drugs are ionized more in alkaline urine‚Äîdo not back diffuse in the kidney tubules and are excreted faster. Accordingly, basic drugs are excreted faster if urine is acidified.</span>
                            </li>
                        </ul>
                        <p>Lipid-soluble nonelectrolytes (e.g. ethanol, diethyl-ether) readily cross biological membranes and their transport is pH independent.</p>

                        <h3>Filtration</h3>
                        <p>Filtration is passage of drugs through aqueous pores in the membrane or through paracellular spaces. This can be accelerated if hydrodynamic flow of the solvent is occurring under hydrostatic or osmotic pressure gradient, e.g. across most capillaries including glomeruli. Lipid-insoluble drugs cross biological membranes by filtration if their molecular size is smaller than the diameter of the pores (Fig. 2.3). Majority of cells (intestinal mucosa, RBC, etc.) have very small pores (4 √Ö) and drugs with MW > 100 or 200 are not able to penetrate. However, capillaries (except those in brain) have large paracellular spaces (40 √Ö) and most drugs (even albumin) can filter through these (Fig. 2.8). As such, diffusion of drugs across capillaries is dependent on rate of blood flow through them rather than on lipid solubility of the drug or pH of the medium.</p>

                        <h3>Specialized transport</h3>
                        <p>This can be carrier mediated or by vesicular transport (endocytosis, exocytosis).</p>

                        <h4>Carrier transport</h4>
                        <p>All cell membranes express a host of transmembrane proteins which serve as carriers or transporters for physiologically important ions, nutrients, metabolites, transmitters, etc. across the membrane. At some sites, certain transporters also translocate xenobiotics, including drugs and their metabolites.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-f0a023d0.jpeg" alt="Illustration of different types of carrier mediated transport across biological membrane" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.5: Illustration of different types of carrier mediated transport across biological membrane (ABC‚ÄîATP-binding cassette transporter; SLC‚ÄîSolute carrier transporter)</figcaption>
                        </figure>

                        <div class="grid grid-2">
                            <div class="grid-item">
                                <h4>Facilitated diffusion</h4>
                                <p>The transporter, belonging to the super-family of solute carrier (SLC) transporters, operates passively without needing energy and translocates the substrate in the direction of its electrochemical gradient, i.e. from higher to lower concentration (Fig. 2.5A). It merely facilitates permeation of a poorly diffusible substrate, e.g. the entry of glucose into muscle and fat cells by the glucose transporter GLUT 4.</p>
                            </div>
                            <div class="grid-item">
                                <h4>Active transport</h4>
                                <p>It requires energy, is inhibited by metabolic poisons, and transports the solute against its electrochemical gradient (low to high), resulting in selective accumulation of the substance on one side of the membrane.</p>
                            </div>
                        </div>

                        <h4>Vesicular transport (endocytosis, exocytosis)</h4>
                        <p>Certain substances with very large or impermeable molecules are transported inside the cell (endocytosis) or extruded from it (exocytosis) by enclosing their particles into tiny vesicles. A binding protein located on the membrane complexes with the substance and initiates vesicle formation (Fig. 2.6). The vesicle then detaches from the membrane and may remain stored within the cell, or it may release the substance in the cytoplasm, or it may move to the opposite membrane fuse with it to release the substance across the cell (exocytosis).</p>
                        
                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-2222adf1.jpeg" alt="Illustration of vesicular transport (endocytosis and exocytosis)" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.6: Illustration of vesicular transport (endocytosis and exocytosis).</figcaption>
                        </figure>
                    </div>
                </section>

                <!-- Section 2: Absorption -->
                <section class="content-section" id="absorption">
                    <div class="section-header">
                        <div class="section-number">02</div>
                        <h2 class="section-title">
                            <span class="title-icon">üì•</span>
                            Absorption
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Absorption is movement of the drug from its site of administration into the circulation. Not only the fraction of the administered dose that gets absorbed, but also the rate of absorption is important. Except when given i.v., the drug has to cross biological membranes; absorption is governed by the above described principles.</p>
                        
                        <h3>Factors affecting absorption</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="list-marker"></span> <strong>Aqueous solubility:</strong> Drugs given in solid form must dissolve in the aqueous biophase before they are absorbed. For poorly water soluble drugs (aspirin, griseofulvin) rate of dissolution governs rate of absorption.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Concentration:</strong> Passive diffusion depends on concentration gradient; drug given as concentrated solution is absorbed faster than from dilute solution.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Area of absorbing surface:</strong> Larger is the surface area, faster is the absorption.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Vascularity of the absorbing surface:</strong> Blood circulation removes the drug from the site of absorption and maintains the concentration gradient across the absorbing surface. Increased blood flow hastens drug absorption.</li>
                            <li class="list-item"><span class="list-marker"></span> <strong>Route of administration:</strong> This affects drug absorption, because each route has its own peculiarities.</li>
                        </ul>

                        <h3>Oral</h3>
                        <p>The effective barrier to orally administered drugs is the epithelial lining of the gastrointestinal tract, which is lipoidal. Nonionized lipid soluble drugs, e.g. ethanol are readily absorbed from stomach as well as intestine at rates proportional to their lipid : water partition coefficient. Acidic drugs, e.g. salicylates, barbiturates, etc. are predominantly unionized in the acid gastric juice and are absorbed from stomach, while basic drugs, e.g. morphine, quinine, etc. are largely ionized and are absorbed only on reaching the duodenum. However, even for acidic drugs absorption from stomach is slower, because the mucosa is thick, covered with mucus and the surface area is small. Absorbing surface area is much larger in the small intestine due to villi. Thus, faster gastric emptying accelerates drug absorption in general. Dissolution is a surface phenomenon, therefore, particle size of the drug in solid dosage form governs rate of dissolution and in turn rate of absorption.</p>
                        <p>Presence of food dilutes the drug and retards absorption. Further, certain drugs form poorly absorbed complexes with food constituents, e.g. tetracyclines with calcium present in milk; moreover food delays gastric emptying. Thus, most drugs are absorbed better if taken in empty stomach. However, there are some exceptions, e.g. fatty food greatly enhances lumefantrine absorption. Highly ionized drugs, e.g. gentamicin, neostigmine are poorly absorbed when given orally.</p>
                        <p>The oral absorption of certain drugs is low because a fraction of the absorbed drug is extruded back into the intestinal lumen by the efflux transporter P-gp located in the gut epithelium. The low oral bioavailability of digoxin and cyclosporine is partly accounted by this mechanism. Inhibitors of P-gp like quinidine, verapamil, erythromycin, etc. enhance, while P-gp inducers like rifampin and phenobarbitone reduce the oral bioavailability of these drugs.</p>

                        <h3>Subcutaneous and Intramuscular</h3>
                        <p>By these routes the drug is deposited directly in the vicinity of the capillaries. Lipid soluble drugs pass readily across the whole surface of the capillary endothelium. Capillaries having large paracellular spaces do not obstruct absorption of even large lipid insoluble molecules or ions (Fig. 2.9A). Very large molecules are absorbed through lymphatics. Thus, many drugs not absorbed orally are absorbed parenterally. Absorption from s.c. site is slower than that from i.m. site, but both are generally faster and more consistent/predictable than oral absorption.</p>

                        <h3>Topical sites (skin, cornea, mucous membranes)</h3>
                        <p>Systemic absorption after topical application depends primarily on lipid solubility of drugs. However, only few drugs significantly penetrate intact skin. Hyoscine, fentanyl, GTN, nicotine, testosterone, and estradiol have been used in this manner. Corticosteroids applied over extensive areas of skin can produce systemic effects and pituitary-adrenal suppression. Absorption can be promoted by rubbing the drug incorporated in an olegenous base or by use of occlusive dressing which increases hydration of the skin.</p>
                    </div>
                </section>

                <!-- Section 3: Bioavailability -->
                <section class="content-section" id="bioavailability">
                    <div class="section-header">
                        <div class="section-number">03</div>
                        <h2 class="section-title">
                            <span class="title-icon">üìä</span>
                            Bioavailability
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Bioavailability refers to the rate and extent of absorption of a drug from a dosage form administered by any route, as determined by its concentration-time curve in blood or by its excretion in urine (Fig. 2.7). It is a measure of the fraction $(F)$ of administered dose of a drug that reaches the systemic circulation in the unchanged form. Bioavailability of drug injected i.v. is 100%, but is frequently lower after oral ingestion because‚Äî</p>
                        <ol class="enhanced-list">
                            <li class="list-item"><span class="list-marker">a</span> The drug may be incompletely absorbed.</li>
                            <li class="list-item"><span class="list-marker">b</span> The absorbed drug may undergo first pass metabolism in the intestinal wall/liver or be excreted in bile.</li>
                        </ol>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-79bd125d.jpeg" alt="Plasma concentration-time curves depicting bioavailability differences between three formulations" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.7: Plasma concentration-time curves depicting bioavailability differences between three formulations of a drug containing the same amount. Formulation B is more slowly absorbed than A. C is absorbed to a lesser extent.</figcaption>
                        </figure>

                        <h3>Bioequivalence</h3>
                        <p>Oral formulations of a drug from different manufacturers or different batches from the same manufacturer may have the same amount of the drug (chemically equivalent) but may not yield the same blood levels‚Äîbiologically inequivalent. Two preparations of a drug are considered bioequivalent when the rate and extent of bioavailability of the active drug from them is not significantly different under suitable test conditions.</p>
                    </div>
                </section>

                <!-- Section 4: Distribution -->
                <section class="content-section" id="distribution">
                    <div class="section-header">
                        <div class="section-number">04</div>
                        <h2 class="section-title">
                            <span class="title-icon">üîÑ</span>
                            Distribution
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Once a drug has gained access to the blood stream, it gets distributed to other tissues that initially had no drug, concentration gradient being in the direction of plasma to tissues. The extent of distribution of a drug and its pattern of tissue distribution depends on its:</p>
                        <ul>
                            <li>lipid solubility</li>
                            <li>ionization at physiological pH (a function of its pKa)</li>
                            <li>extent of binding to plasma and tissue proteins</li>
                            <li>presence of tissue-specific transporters</li>
                            <li>differences in regional blood flow.</li>
                        </ul>

                        <h3>Apparent volume of distribution (V)</h3>
                        <p>Presuming that the body behaves as a single homogeneous compartment with volume $V$ into which the drug gets immediately and uniformly distributed</p>
                        
                        <div class="equation">
                            $$\mathrm{V}=\frac{\text { dose administered i.v. }}{\text { plasma concentration }}$$
                        </div>

                        <p>Since in the example shown in Fig. 2.8, the drug does not actually distribute into 20 L of body water, with the exclusion of the rest of it, this is only an apparent volume of distribution which can be defined as "the volume that would accommodate all the drug in the body, if the concentration throughout was the same as in plasma".</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-49f0433e.jpeg" alt="Illustration of the concept of apparent volume of distribution" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.8: Illustration of the concept of apparent volume of distribution (V). In this example, 1000 mg of drug injected i.v. produces steady-state plasma concentration of 50 mg/L, apparent volume of distribution is 20 L.</figcaption>
                        </figure>

                        <h3>Redistribution</h3>
                        <p>Highly lipid-soluble drugs get initially distributed to organs with high blood flow, i.e. brain, heart, kidney, etc. Later, less vascular but more bulky tissues (muscle, fat) take up the drug‚Äîplasma concentration falls and the drug is withdrawn from the highly perfused sites. If the site of action of the drug was in one of the highly perfused organs, redistribution results in termination of drug action. Greater the lipid solubility of the drug, faster is its redistribution. Anaesthetic action of thiopentone sod. injected i.v. is terminated in few minutes due to redistribution.</p>

                        <h3>Penetration into brain and CSF</h3>
                        <p>The capillary endothelial cells in brain have tight junctions and lack large paracellular spaces. Further, an investment of neural tissue (Fig. 2.9B) covers the capillaries. Together they constitute the so called blood-brain barrier (BBB). A similar blood-CSF barrier is located in the choroid plexus. Both these barriers are lipoidal and limit the entry of nonlipid-soluble drugs, e.g. streptomycin, neostigmine, etc. Only lipid-soluble drugs, therefore, are able to penetrate and have action on the central nervous system.</p>

                        <figure class="content-figure" data-lightbox="true">
                            <div class="figure-image-wrapper">
                                <img src="../assets/images/image-20251214-57116848.jpeg" alt="Passage of drugs across capillaries" class="figure-image">
                                <div class="figure-overlay">
                                    <span class="overlay-icon">üîç</span>
                                    <span class="overlay-text">Click to enlarge</span>
                                </div>
                            </div>
                            <figcaption class="figure-caption">Fig. 2.9: Passage of drugs across capillaries. A. Usual capillary with large paracellular spaces. B. Capillary constituting blood brain barrier with tight junctions.</figcaption>
                        </figure>
                    </div>
                </section>

                <!-- Section 5: Plasma Protein Binding -->
                <section class="content-section" id="protein-binding">
                    <div class="section-header">
                        <div class="section-number">05</div>
                        <h2 class="section-title">
                            <span class="title-icon">üîí</span>
                            Plasma Protein Binding & Storage
                        </h2>
                    </div>

                    <div class="content-card">
                        <p>Most drugs possess physicochemical affinity for plasma proteins and get reversibly bound to these. Acidic drugs generally bind to plasma albumin and basic drugs to $\alpha_{1}$ acid glycoprotein.</p>

                        <div class="table-responsive">
                            <table class="comparison-table">
                                <thead>
                                    <tr>
                                        <th>To albumin</th>
                                        <th>To $\alpha_{1}$-acid glycoprotein</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Barbiturates</td>
                                        <td>$\beta$-blockers</td>
                                    </tr>
                                    <tr>
                                        <td>Benzodiazepines</td>
                                        <td>Bupivacaine</td>
                                    </tr>
                                    <tr>
                                        <td>NSAIDs</td>
                                        <td>Lidocaine</td>
                                    </tr>
                                    <tr>
                                        <td>Valproic acid</td>
                                        <td>Disopyramide</td>
                                    </tr>
                                    <tr>
                                        <td>Phenytoin</td>
                                        <td>Imipramine</td>
                                    </tr>
                                    <tr>
                                        <td>Penicillins</td>
                                        <td>Methadone</td>
                                    </tr>
                                    <tr>
                                        <td>Sulfonamides</td>
                                        <td>Prazosin</td>
                                    </tr>
                                    <tr>
                                        <td>Tetracyclines</td>
                                        <td>Quinidine</td>
                                    </tr>
                                    <tr>
                                        <td>Tolbutamide</td>
                                        <td>Verapamil</td>
                                    </tr>
                                    <tr>
                                        <td>Warfarin</td>
                                        <td></td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <h3>Clinical Implications</h3>
                        <ul class="enhanced-list">
                            <li class="list-item"><span class="list-marker"></span> Highly plasma protein bound drugs are largely restricted to the vascular compartment.</li>
                            <li class="list-item"><span class="list-marker"></span> The bound fraction is not available for action.</li>
                            <li class="list-item"><span class="list-marker"></span> High degree of protein binding generally makes the drug long acting, because bound fraction is not available for metabolism or excretion.</li>
                            <li class="list-item"><span class="list-marker"></span> One drug can bind to many sites on the albumin molecule. This can give rise to displacement interactions among drugs bound to the same site(s).</li>
                            <li class="list-item"><span class="list-marker"></span> In hypoalbuminemia, binding may be reduced and high concentrations of free drug may be attained.</li>
                        </ul>

                        <h3>Tissue storage</h3>
                        <p>Drugs may also accumulate in specific organs by active transport or get bound to specific tissue constituents.</p>
                        <div class="table-responsive">
                            <table class="content-table">
                                <thead>
                                    <tr>
                                        <th>Tissue</th>
                                        <th>Drug</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Skeletal muscle, heart</td>
                                        <td>digoxin, emetine (bound to muscle proteins)</td>
                                    </tr>
                                    <tr>
                                        <td>Liver</td>
                                        <td>chloroquine, tetracyclines, emetine, digoxin</td>
                                    </tr>
                                    <tr>
                                        <td>Kidney</td>
                                        <td>digoxin, chloroquine, emetine</td>
                                    </tr>
                                    <tr>
                                        <td>Thyroid</td>
                                        <td>iodine</td>
                                    </tr>
                                    <tr>
                                        <td>Brain</td>
                                        <td>chlorpromazine, acetazolamide, isoniazid</td>
                                    </tr>
                                    <tr>
                                        <td>Retina</td>
                                        <td>chloroquine (bound to nucleoproteins)</td>
                                    </tr>
                                    <tr>
                                        <td>Iris</td>
                                        <td>ephedrine, atropine (bound to melanin)</td>
                                    </tr>
                                    <tr>
                                        <td>Bone and teeth</td>
                                        <td>tetracyclines, heavy metals (bound to mucopolysaccharides), bisphosphonates (bound to hydroxyapatite)</td>
                                    </tr>
                                    <tr>
                                        <td>Adipose tissue</td>
                                        <td>thiopentone, ether, minocycline, phenoxybenzamine, DDT</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <!-- Problem Directed Study -->
                <section class="content-section" id="problem-study">
                    <div class="section-header">
                        <div class="section-number">06</div>
                        <h2 class="section-title">
                            <span class="title-icon">üß©</span>
                            Problem Directed Study
                        </h2>
                    </div>

                    <div class="content-card">
                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ùì</span>
                                <h4 class="callout-title">Case Study 2.1</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 60-year-old woman complained of weakness, lethargy and easy fatigability. Investigation showed that she had iron deficiency anaemia (Hb 8 g/dl). She was prescribed cap. ferrous fumarate 300 mg twice daily. She returned after one month with no improvement in symptoms. Her Hb level was unchanged. On enquiry she revealed that she felt epigastric distress after taking the iron capsules, and had started taking antacid tablets along with the capsules.</p>
                                <p><strong>(a) What could be the possible reason for her failure to respond to the oral iron medication?</strong></p>
                            </div>
                        </div>

                        <div class="callout callout--warning">
                            <div class="callout-header">
                                <span class="callout-icon">‚ùì</span>
                                <h4 class="callout-title">Case Study 2.2</h4>
                            </div>
                            <div class="callout-content">
                                <p>A 50-year-old type-2 diabetes mellitus patient was maintained on tab. glibenclamide (a sulfonylurea) 5 mg twice daily. He developed toothache for which he took tab. aspirin 650 mg 6 hourly. After taking aspirin he experienced anxiety, sweating, palpitation, weakness, ataxia, and was behaving abnormally. These symptoms subsided when he was given a glass of glucose solution.</p>
                                <p><strong>(a) What could be the explanation for his symptoms?</strong><br>
                                <strong>(b) Which alternative analgesic should have been taken?</strong></p>
                                <p><em>(See Appendix-1 for solutions)</em></p>
                            </div>
                        </div>
                    </div>
                </section>
            </main>

            <nav class="document-nav">
                <div class="nav-container">
                    <a href="topic-01-introduction.html" class="nav-button nav-button--large nav-button--previous">
                        <div class="nav-label">Previous</div>
                        <div class="nav-title">Introduction & Routes</div>
                    </a>
                    
                    <div class="document-progress">
                        <div class="progress-indicator">
                            <span>2</span>
                            <span class="progress-separator">/</span>
                            <span>13</span>
                        </div>
                        <div class="progress-bar-container">
                            <div class="progress-bar-fill" style="width: 15.3%;"></div>
                        </div>
                        <div class="progress-label">Topic Progress</div>
                    </div>
                    
                    <a href="topic-03-pharmacokinetics-metabolism.html" class="nav-button nav-button--large nav-button--next">
                        <div class="nav-label">Next</div>
                        <div class="nav-title">Metabolism & Excretion</div>
                    </a>
                </div>
            </nav>
        </article>
    </div>
</div>

<!-- Lightbox Modal -->
<div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
    <div class="lightbox-backdrop"></div>
    <div class="lightbox-content">
        <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
        <img class="lightbox-image" src="" alt="">
        <p class="lightbox-caption"></p>
    </div>
</div>

<script src="../js/theme.js"></script>
<script src="../js/navigation.js"></script>
<script src="../js/interactions.js"></script>
</body>
</html>
